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Abstract  
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its 
effect through targeted accumulation in the liver. Current United States and Canadian dosing 
guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, 
we demonstrate for the first time that concomitant administration with food substantially 
reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian 
subjects. In mice lower plasma level was also noted with food 2 hours after an oral 
rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective 
analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as 
opposed to on an empty stomach, does not significantly affect the cholesterol-lowering 
capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle 
pain/damage associated with high circulating statin levels, our findings have the potential to 
serve as a novel and simple strategy for mitigating statin myopathy risk.  
Keywords: rosuvastatin, HMG-CoA reductase inhibitors, oral pharmacokinetics, food effect, 
hepatic uptake transport, drug transporter pharmacogenetics. 
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1. INTRODUCTION  
1.1. Cardiovascular Disease & Dyslipidemia  
Cardiovascular disease, including both heart disease and stroke, is the second leading 
cause of mortality in Canada (Maclagan et al., 2014). Moreover, cardiovascular disease 
is associated with disability, decreased quality of life, and an annual economic burden of 
approximately $22 billion in lost productivity and direct/indirect healthcare costs (Genest 
et al., 2009). A major implication in the development of cardiovascular disease is 
dyslipidemia, or abnormal amount of lipids and lipoproteins in the blood. Specifically, 
high plasma low-density lipoprotein cholesterol (LDL-C; “bad cholesterol”), low levels 
of high-density lipoprotein cholesterol (HDL-C; “good cholesterol”), and elevated 
triglycerides have been indicated as independent predictors of cardiovascular disease 
(Sharrett et al., 2001; Gordon et al., 1989; Sarwar et al., 2007). Current therapy 
emphasizes lifestyle modifications (i.e. healthy diet, regular exercise, avoidance of 
cigarette smoke etc.) and the use of pharmacotherapy to lower circulating LDL-C 
concentrations (Stone et al., 2014).   
Elevated plasma LDL-C is the result of a disturbance in the intricate balance between 
endogenous and exogenous cholesterol metabolism (Shepard, 2001). Exogenous 
cholesterol is largely derived from the intestinal absorption of both bile acids and dietary 
sources; this newly absorbed cholesterol is then packaged with an array of specialty 
proteins and delivered to the liver for processing (Grundy, 1978). The liver also 
synthesizes the majority of systemic cholesterol through an endogenous pathway. 
Cholesterol synthesis begins with the conversion of acetyl CoA to 3-hydroxy-3-
methylglutaryl CoA (HMG-CoA), which is then reduced to mevalonic acid. The 
mevalonic acid is further converted into cholesterol through a complex sequence of 
condensation reactions (Grundy, 1978). The conversion of HMG-CoA to mevalonic acid 
by HMG-CoA reductase is widely accepted as the rate-limiting step in cholesterol 
biosynthesis and, as such, is the target for leading cholesterol-lowering therapies. 
!2
Several classes of lipid-modifying medications are currently available, including fibrates 
(e.g. gemfibrozil, fenofibrate), nicotinic acid (e.g. niceritrol, niacin), bile acid 
sequestrants (e.g. cholestyramine, colestipol), and cholesterol absorption inhibitors (e.g. 
ezetimibe). However, statins (i.e. rosuvastatin, atorvastatin, simvastatin etc.) are the most 
commonly prescribed class of medications for the treatment of hypercholesterolemia 
(Law et al., 2003). 
1.2. Statin Pharmacology  
Statin medications are first-line therapy for cardiovascular disease prevention, and an 
estimated 25.2 million Americans are currently receiving statin therapy (Pencina et al., 
2014). However, statin use has been associated with reductions in LDL-C, cardiovascular 
events, and all-cause mortality, providing strong evidence to support statin use as primary 
prevention in people at low risk of cardiovascular disease (Taylor et al., 2013). Thus, new 
guidelines from the American College of Cardiology and the American Heart Association 
recommend broadening the use of statin therapy to include an additional 30.8 million 
Americans in addition to those already receiving statins (Stone et al., 2014; Pencina et 
al., 2014). An overview of statin mechanism of action, their potential for adverse effects, 
pharmacokinetics (PK), and pharmacogenetics (PGx) is presented below.  
1.2.1. Mechanism of Action  
Statins exert their pharmacological effect by competitively inhibiting HMG-CoA 
reductase, decreasing cholesterol production. A lower regulatory pool of cholesterol is 
sensed by specialized proteins within the endoplasmic reticulum and results in the 
activation of sterol regulatory element binding protein 2 (SREBP2). In its activated state, 
SREBP2 acts as a nuclear transcription factor which functions to increase the expression 
of LDL receptors (LDL-R) on the basolateral membrane of hepatocytes. SREBP2 
activation also increases the expression HMG-CoA reductase, however cholesterol 
production does not increase due to competitive inhibition by the statin. Newly 
synthesized LDL-R function to clear circulating LDL-C, resulting in lower blood levels 
of this atherogenic particle (Goldstein & Brown, 2009). A schematic of the primary 
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mechanism of action of statins is presented in Figure 1. In addition to lowering LDL-C, a 
number of pleiotropic effects of statins have been identified including: increased stability 
of arterial plaque, decreased oxidative stress and inflammation, and improved endothelial 
function (Takemoto & Liao, 2001). 
!4
Figure 1.  Endogenous cholesterol synthesis and the primary mechanism of action of 
statin medications. Adapted from DeGorter, 2012a. 
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In Canada, current guidelines list statins as the first-line pharmacotherapy for the 
treatment of dyslipidemia. Moreover, guidelines recommend a target LDL-C less than 2 
mmol/L, or greater than 50% reduction of LDL-C from untreated baseline (Anderson et 
al., 2013). This therapeutic target is often achieved through statin monotherapy, as statins 
have been shown to lower systemic cholesterol by an average of 1.8 mmol/L; this 
reduction correlates clinically with an average decrease in ischemic heart disease of 
~60% and stroke by ~17% (Law et al., 2003). Although an individual’s LDL-C reduction 
is typically used as a measure of statin response, plasma concentrations of lathosterol, a 
cholesterol biosynthesis intermediate, can be used to indicate the rate of endogenous 
cholesterol synthesis and, thus, the response to statin therapy (De Cuyper et al., 1993). 
1.2.2. Adverse Side Effects  
In 2012 an estimated 200 million individuals benefitted from statin use worldwide 
(Sirtori et al., 2012). The expansive use of statins to lower serum cholesterol is often 
attributed to their ability to favourably alter multiple aspects of a patient’s cholesterol 
profile and maintain a relatively low adverse-effect (AE) frequency (Evans & Rees, 
2002). However, up to 10% of statin patients experience muscle-related AEs and, 
consequently, require dose adjustment, a switch to an alternate statin medication, or 
cessation of statin therapy (Joy & Hegele, 2009). Muscle-related toxicities (myopathies) 
include myalgia (muscle pain) and, occurring in a small number of individuals, 
rhabdomyolysis (muscle breakdown). Rhabdomyolysis often presents as an 
asymptomatic elevation of serum muscle enzymes, however in more severe cases 
resultant acute renal failure and electrolyte abnormalities can be life threatening 
(Polderman, 2004). Of note, cerivastatin was withdrawn from the market in 2001 due to 
an increased risk (approximately 12-fold) of both asymptomatic and fatal rhabdomyolysis 
when compared to other statins (Kashani et al., 2006). It is suggested that the risk of 
myopathy may be higher for lipophilic statins likely due, in part, to an increased ability to 
enter muscle cells (Kobayashi et al., 2008). However, even hydrophilic statins such as 
rosuvastatin are known to cause both myalgia and rhabdomyolysis (García-Rodríguez et 
al., 2008). Interestingly, the uptake transporter OATP2B1 is present on the sarcolemmal 
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membrane of human skeletal muscle fibers and is thought to play a key role in 
modulating skeletal muscle statin exposure and toxicity (Knauer et al., 2010). Substrates 
for OATP2B1 include atorvastatin, fluvastatin, pravastatin, and rosuvastatin (Knauer, 
2012). 
Time to onset of statin-induced muscle toxicity varies widely, but on average myopathy is 
thought to occur around 6 months after beginning therapy (Hansen et al., 2005). Statin-
induced myopathy can result in structural damage to muscle fibres, which is thought to 
persist even if statin use is discontinued (Mohaupt et al., 2009). Although the exact 
mechanism of statin-induced muscle-related toxicities is unknown (Tomaszewski et al., 
2011), myopathy is associated with higher statin dose and increased plasma statin 
exposure (Jacobson, 2006). Elevated plasma exposure can result from either increased 
absorption or, more commonly, decreased clearance of the statin. Factors that may affect 
statin exposure are discussed at length in later sections.  
1.2.3. Pharmacokinetics  
Statins are commonly administered once daily via an oral dose. Most statins are 
administered in their active, hydroxy-acid form, however simvastatin and lovastatin are 
administered as lactone pro-drugs (Schachter, 2005). Although statin medications share a 
common mechanism of action, they differ in terms of their chemical structure, binding 
efficacy, pharmacokinetic properties, and lipid-modifying capacity. Pharmacokinetic 
properties for the six statin medications currently available in Canada are summarized in 
Table 1.  
Lipophilicity of statins influences their absorption, distribution, metabolism, and 
excretion. Atorvastatin, simvastatin, fluvastatin, and lovastatin are relatively lipophilic 
compounds and can thus readily diffuse through biological membranes. Hydrophilic 
rosuvastatin and pravastatin, however, require carrier-mediated transport to transverse 
cellular membranes (Hamelin & Turgeon, 1998). Due to the high expression of statin 
transporters on hepatocytes, rosuvastatin and pravastatin show greater hepatoselectivity 
and reduced potential for uptake by peripheral cells when compared to lipophilic statins 
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(Nezasa et al., 2003). Nevertheless, all statins currently available in Canada demonstrate 
carrier mediated transport to some extent and therefore expression and activity of these 
transporters on various tissues greatly impact statin disposition (Rodrigues, 2010). 
Statin oral bioavailability ranges from less than 5% for simvastatin up to approximately 
30% for fluvastatin (Mauro, 1993; Scripture & Pieper, 2001; Rosenson, 2003). These low 
values are attributed to extensive gut metabolism and efficient extraction by the liver 
(Shitara & Sugiyama, 2006). Since statins act in the liver, first-pass hepatic uptake of 
statin medications is likely more important than oral bioavailability. Uptake transporters 
expressed on the basolateral membrane of hepatocytes are important for portal extraction 
of statins by the liver. Specifically, members of the organic anion-transporting 
polypeptide family (OATP1B1, OATP1B3, OATP2B1), and the sodium-taurocholate 
cotransporting polypeptide (NTCP) are implicated in statin transport into hepatocytes 
(DeGorter, 2012a). Following hepatic metabolism, statins are predominantly removed 
from the body via biliary excretion (Schachter, 2005). ATP-binding cassette (ABC) efflux 
transporters located on the canalicular membrane of hepatocytes mediate the 
hepatobiliary excretion of statins (DeGorter, 2012a). Figure 2 details the hepatic uptake 
and efflux transporters important for statin disposition.  
Both lipophilic and hydrophilic statins exhibit extensive plasma protein binding, ranging 
from approximately 50% for pravastatin up to greater than 98% for atorvastatin and 
fluvastatin (Hatanaka, 2000; Lennernäs, 2003; Rosenson, 2003). However, lipophilic 
statins are more prone to oxidative metabolism by the cytochrome P450 (CYP) family of 
enzymes (Schachter, 2005). Indeed, atorvastatin, simvastatin, and lovastatin are 
metabolized by the CYP3A4 isozyme whereas fluvastatin is predominantly metabolized 
by the CYP2C9 isozyme. Alternatively, hydrophilic pravastatin and rosuvastatin are not 
significantly metabolized by CYP enzymes (Rosenson, 2003).  
Clinical factors including progressive liver and renal disease can alter statin 
pharmacokinetics. Of note, the package insert for atrovastatin (Lipitor®) suggests that the 
maximum plasma concentration (Cmax) and area under the plasma concentration-time 
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curve (AUC) values are 4-fold greater in patients with well-compensated cirrhosis 
(Childs-Pugh A disease), and approximately 16-fold and 11-fold higher, respectively, in 
patients with significant functionally compromised cirrhosis (Childs-Pugh B disease). 
Product monographs for all six statin medications currently available in Canada state that 
statin use is contraindicated in individuals with active liver disease. Moreover, dosage 
guidelines for all available statins, except for atorvastatin, recommend lower doses for 
individuals with severe (or in some cases moderate) renal impairment. In addition to 
concomitant disease, other factors that may influence statin pharmacokinetics include 
genetics, ethnicity, age, sex, and food intake (DeGorter et al., 2013; Gazzerro et al., 
2012).  
!10
 
Figure 2.  Hepatic uptake and efflux transporters important for statin disposition. 
Abbreviations: OATP, organic anion-transporting polypeptide; NTCP, sodium 
taurocholate cotransporting polypeptide; BCRP, breast cancer resistance protein; P-gp, P-
glycoprotein; MRP, multidrug resistance-associated protein. Adapted from DeGorter, 
2012a. 
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1.2.4. Pharmacogenetics  
Single nucleotide polymorphisms (SNPs) in statin transporters have been associated with 
altered disposition of, and response to, statin medications. In particular, loss-of-function 
SNPs within ABCG2, particularly c.421C>A (rs22331142) and c.34G>A (rs2231137), 
have been found to impact statin pharmacokinetics. ABCG2 codes for BCRP, an efflux 
transporter that appears to limit the absorption, entry, or retention of endogenous and 
exogenous substrates into various tissue compartments (Mao & Unadkat, 2015). In vitro 
work suggests that ABCG2 c.421C>A significantly impairs BCRP protein expression 
without altering mRNA expression (Kondo et al., 2004). Clinically, increased AUCs for 
atorvastatin, fluvastatin, simvastatin lactone, and rosuvastatin were greater in c.421A/A 
individuals than in c.421C/C individuals (Keskitalo et al., 2009a; Keskitalo et al., 2009b). 
Moreover, in individuals taking rosuvastatin to manage their hypercholesterolemia, the c.
421C>A variant has been found to correlate in a gene dose-dependent manner with 
reductions in LDL-C (Bailey et al., 2010; Tomlinson et al., 2010). ABCG2 c.34G>A has 
been associated with decreased localization of BCRP to the apical membrane of polarized 
kidney cells in vitro (Mizuarai et al., 2004). A recent study in healthy Chinese volunteers 
shows that mean rosuvastatin AUC and maximum concentration are higher in ABCG2 c.
34AA, c.421AA, and c.34GA/421CA individuals when compared to non-carriers (Wan et 
al., 2015). 
Within SLCO1B1, both a loss-of-function polymorphism (c.521T>C; rs4149056) and a 
gain-of-function polymorphism (c.388A>G; rs2306283) have been shown to impact 
statin pharmacokinetics. SLCO1B1 codes for OATP1B1, which is largely expressed at the 
basolateral membrane of hepatocytes and mediates the uptake of its substrates from portal 
circulation into the liver (Gong & Kim, 2013). In vitro work suggests that c.521T>C 
reduces transporter expression at the plasma membrane of HeLa cells and consequently 
impairs transport activity of several OATP1B1 substrates (Tirona et al., 2001). Clinically, 
c.521T>C has been associated with increased AUC of simvastatin acid in healthy 
volunteers (Pasanen et al., 2006). A large genome-wide association study revealed c.
521T>C as a strong predictor of simvastatin-induced myopathy in statin patients and 
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estimated an increased 5 year cumulative risk for myopathy in individuals with one or 
two alleles by 3% and 18% respectively (Link et al., 2008). Moreover, mean atorvastatin 
and rosuvastatin AUCs were found to be 144% and 65% higher, respectively, in c.521CC 
individuals when compared to individuals that did not carry the c.521T>C variant 
(Pasanen et al., 2007). In contrast, SLCO1B1 c.388A>G has been associated with 
increased expression of hepatic OATP1B1 in a Caucasian population (Nies et al., 2013). 
SLCO1B1 c.388A>G is associated with lower plasma concentrations of various statins 
(Maeda et al., 2006; Tornio et al., 2015). Moreover, carriers of two variant alleles have 
shown increased LDL-C reduction in response to atorvastatin treatment when compared 
with carriers of one or fewer variant alleles (Rodrigues et al., 2011). Furthermore, 
SLCO1B1 c.521T>C and c.388A>G are in linkage disequilibrium and can exist as 4 
distinct haplotypes (Table 2) with varying affects on both statin disposition and response 
(Gong & Kim, 2013). Of note, SLCO1B1 c.388A>G + c.521T>C (*15) is associated with 
decreased transport activity and increased AUC of various statins when compared to wild 
type (Romaine et al., 2010). 
Although select statins are extensively metabolized by members of the CYP enzyme 
family, evidence regarding the effect of polymorphisms within CYP encoding genes on 
statin response remains conflictive and inconclusive (Mangravite et al., 2006). 
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Table 2.  Nucleotide and amino acid changes present in the *1a, *1b, *5, and *15 
haplotypes of SLCO1B1. 
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1.3.  Statin-Food Effects 
Proper adherence to medication regimens can significantly impact health outcomes, and 
linking drug doses to aspects of an individual’s daily routine, such as meal times, can 
improve compliance (Cramer, 1998). However, taking a medication with food may result 
in alterations in the physiochemical properties of the drug, and/or changes to the 
pharmacokinetics or pharmacodynamic profiles of the drug (Figure 3). These alterations 
may have clinical implications such as adverse drug reactions or decreased therapeutic 
efficacy (Singh, 1999). Moreover, the caloric and nutrient contents of a co-administered 
meal, along with the physical properties of the meal (size, temperature etc.), can 
influence a medication’s gastrointestinal-transit time, luminal dissolution, tissue 
permeability, and systemic availability. Common mechanisms for food-drug interactions 
include changes in gastric emptying or pH, alterations in bile flow and/or splanchnic 
blood flow, physical or chemical interactions between the medication and food 
components, and alterations in drug metabolism and/or transport (Winstanley & Orme, 
1989; Singh, 1999). The Food and Drug Administration recognized the potential for food 
to effect the oral pharmacokinetics of new medications and has established standards for 
the design and execution of clinical food-effect studies (Food and Drug Administration, 
2002). 
Grapefruit juice-drug interactions are perhaps the most extensively studied. Grapefruit 
juice can increase systemic drug exposure by up to 14-fold by inhibiting CYP3A-
mediated metabolism within the small intestine (Won et al., 2010). The CYP3A-
subfamily is thought to be involved in the oxidative metabolism of over 50% of 
medications, including three of the six statins currently available in Canada (Won et al., 
2010). Indeed, product monographs for Lipitor® (atorvastatin), Zocor ® (simvastatin), 
and Mevacor® (lovastatin), caution against grapefruit juice consumption. Aside from 
grapefruit juice effects, few statin-food interactions have been reported. Food interactions 
with the six statins available in Canada (lovastatin, pravastatin, fluvastatin, simvastatin, 
atorvastatin, and rosuvastatin) are reviewed below. 
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Figure 3.  Working model of drug-food interactions. Adapted from Boullata & 
Hudson, 2012. 
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1.3.1. Lovastatin  
When lovastatin was given under fasted conditions, plasma concentrations of the parent 
drug and its active metabolite (lovastatin acid) were approximately two-thirds those 
found when lovastatin was administered with food (Mevacor® product monograph). 
Thus, current recommendations suggest that lovastatin be taken with food in order to 
enhance bioavailability of the medication. However, ingestion of a standard breakfast 
with lovastatin extended release tablets decreased Cmax and AUC by approximately 40% 
when compared to values obtained from fasted administration (Sun et al., 2002). High 
intake of dietary fibre has been shown to reduce the LDL-C lowering effect of lovastatin 
in hyperlipidemic patients (Richter et al., 1991). Moreover, grapefruit juice can 
significantly increase plasma concentrations of lovastatin and lovastatin acid, likely due 
to inhibition of intestinal CYP3A4 (Kantola et al., 1998). 
1.3.2. Pravastatin  
Administration of pravastatin with food resulted in a 49% and 31% reduction in Cmax and 
AUC, respectively, when compared to administration one hour before a meal, without 
affecting the LDL-C actions of pravastatin (Pan et al., 1993). Consequently, current 
recommendations suggests that pravastatin may be taken without regard to food. Not 
surprisingly, due to its limited metabolism, grapefruit juice does not significantly affect 
pravastatin pharmacokinetics (Lilja et al., 1999). 
1.3.3. Fluvastatin  
Current dosing guidelines indicate no preference for fed or fasted administration of 
fluvastatin. Peak serum concentrations of fluvastatin were lower in primary 
hypercholesterolemic patients that took their dose with an evening meal when compared 
to a fasted administration. However, taking fluvastatin with or without food did not 
significantly affect its extent of bioavailability or the ability to lower LDL-C within these 
patients (Dujovne & Davidson, 1994). Interestingly, one study found that fluvastatin 
treatment in rats fed a high-fat diet led to increased systemic exposure, skeletal muscle 
toxicity, and hepatic steatosis accompanied by severe hepatotoxicity (Sugatani et al., 
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2010). Authors from this work also found that the expression of mRNA and protein of the 
rat hepatic uptake transporter, Oatp2, was suppressed in high-fat fed rats administered 
fluvastatin. Reduced hepatic uptake could explain the increased systemic exposure and 
muscle toxicity, whereas hepatic steatosis and hepatotoxicity within rats have been shown 
to result from prolonged high-fat feeding (Sugatani et al., 2010). 
1.3.4. Simvastatin  
Although the data are sparse, a few reports indicate that concomitant food administration 
with simvastatin does not significantly affect simvastatin pharmacokinetics or therapeutic 
action (Corsini et al., 1999; Zocor® product monograph). Of note, grapefruit juice 
increased the mean Cmax and AUC of unchanged simvastatin by approximately 9-fold and 
16-fold respectively. Moreover, mean peak serum concentration and total systemic 
exposure of simvastatin acid were also increased by approximately 7-fold each by 
grapefruit juice consumption (Lilja et al., 1998). Additionally, rats fed capsaicin (a main 
ingredient in chili peppers) daily for one week before simvastatin treatment demonstrated 
reduced Cmax and AUC for both simvastatin and its acid metabolite when compared to 
controls. Authors from this work hypothesize that capsaicin may be a potent inducer of 
select CYP3A enzymes and thus cause increased metabolism of simvastatin (Zhai et al., 
2013).  
1.3.5. Atorvastatin  
Guidelines for atorvastatin dosing indicate no preference for fed or fasted administration. 
In healthy volunteers, administration of atorvastatin with food resulted in Cmax and AUC 
values that were 48% and 13% lower, respectively, than values attained when atorvastatin 
was administered without food (Radulovic et al., 1995). In another study, administration 
with food was found to similarly affect atorvastatin pharmacokinetics, but LDL-C 
reduction was similar when atorvastatin was administered with or without food 
(Whitfield et al., 2000). Moreover, grapefruit juice significantly increased plasma 
concentrations of atorvastatin acid and atorvastatin lactone (Lilja et al., 1999). 
!18
1.3.6. Rosuvastatin  
Current United States and Canadian manufacturer guidelines indicate no preference for 
fed or fasted rosuvastatin administration. Moreover, within the Food and Drug 
Administration (FDA) approval package for Crestor® (rosuvastatin calcium), it states 
that administration with food does not alter the systemic exposure of rosuvastatin (Center 
for Drug Evaluation and Research, 2012). However, one study performed in healthy 
Chinese volunteers indicates a drastic decrease in rosuvastatin plasma concentrations 
(both Cmax and AUC) when  rosuvastatin is administered with food compared to fasted 
administration (Li et al., 2009). Similarly, a recent study in dogs demonstrated lower 
statin plasma exposure when  rosuvastatin is administered with food, including both low- 
and high-fat meals, with the latter having the greater effect on rosuvastatin plasma 
concentrations (Baek et al., 2013). 
!19
2. RATIONALE, SPECIFIC AIMS, & HYPOTHESES  
2.1.  Rationale  
Statin medications target the liver to competitively inhibit the rate-limiting enzyme in the 
cholesterol biosynthesis pathway, HMG-CoA reductase, and are commonly prescribed to 
manage hypercholesterolemia. The extensive use of statins is often attributed to their 
ability to significantly reduce cardiovascular event risk by lowering plasma levels of low-
density lipoprotein cholesterol (Law et al., 2003). A notable barrier to statin therapy is 
skeletal muscle toxicity, which is associated with increased systemic statin exposure 
(Jacobson, 2006). Indeed, up to 10% of statin patients experience some degree of muscle 
pain or weakness (Joy & Hegele, 2009). 
Rosuvastatin is a synthetic statin that demonstrates high hepatic selectivity and minimal 
metabolism. Moreover, rosuvastatin is one of the most potent statins and has 
demonstrated superior cholesterol lowering abilities when compared to other statins on 
the market (Barakat et al., 2013; McKenney, 2005). Consequently, many physicians have 
taken to prescribing rosuvastatin ahead of other statin medications, making rosuvastatin 
the number one most prescribed statin (and the second most prescribed medication 
overall) in Canada in 2010 (IMS Health Canada, 2010).  
Current dosing guidelines for rosuvastatin indicate no preference for fed or fasted 
administration (Center for Drug Evaluation and Research, 2012), but recent 
pharmacokinetic data suggest that rosuvastatin systemic exposure is significantly reduced 
when administered with food (Li et al., 2009; Baek et al., 2013). It was concluded that 
this food effect was likely a result of decreased intestinal absorption of rosuvastatin (Li et 
al., 2009; Baek et al., 2013). However, lower systemic exposure could also be explained 
by increased hepatic clearance of rosuvastatin. 
Our group was the first to demonstrate that a liver-specific uptake transporter known as 
NTCP, was capable of mediating the hepatic uptake of rosuvastatin (Ho et al., 2006). 
Although the OATP family of transporters, including OATP1B1, has been viewed as the 
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principal mediators for the hepatic uptake of statins, previous data in our lab 
demonstrated that NTCP may account for nearly one third of rosuvastatin uptake (Ho et 
al., 2006). NTCP is a major transporter involved in the enterohepatic recirculation of bile 
acids, and its expression and activity are highly regulated by the presence or absence of 
bile acids after food ingestion. We now know that much of its activity is regulated in a 
highly dynamic fashion through insertion and retrieval from the hepatocyte basolateral 
membrane, allowing efficient management of a high bile-acid load associated with food 
ingestion (Anwer & Stieger, 2014). Due to the fact that NTCP is expressed on the 
basolateral membrane of hepatocytes, increased expression or activity would aid in the 
clearance of statins from the portal circulation, while lowering circulating statin 
concentrations. Therefore, although concomitant administration of food may decrease 
intestinal absorption of rosuvastatin, food may also stimulate rosuvastatin hepatic uptake. 
Furthermore, since statins function through targeted accumulation in the liver (Ho et al., 
2006), a treatment regime which allows for increased hepatic uptake (and consequently, 
reduced systemic exposure) of the statin may increase efficacy while mitigating statin-
induced muscle adverse effects. 
To date, food effect for rosuvastatin has been evaluated only in dogs and in a Chinese 
population (Baek et al., 2013; Li et al., 2009), in which rosuvastatin clearance is known 
to differ from Caucasians (Lee et al., 2005). Moreover, the study performed in Chinese 
subjects used generic rosuvastatin provided by DYNE PHARMA (Shandong, China), 
rather than the brandname product, Crestor®, commonly used in North America. 
Therefore, the objectives for the present work were to determine the effect of 
concomitantly administered food on rosuvastatin pharmacokinetics in Canadian East 
Asian individuals and to elucidate this effect, for the first time, in Caucasian individuals. 
Moreover, we sought to investigate the effect of concomitant food administration with 
rosuvastatin dose on the lipid profiles of statin patients. Finally, we wished to examine a 
possible food effect within mice.  
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2.2.  Specific Aims & Hypotheses  
2.2.1. Specific Aim 1  
Determine the effect of concomitant food administration, and type of meal 
administered (high-fat versus low-fat), on plasma rosuvastatin concentrations in 
healthy Canadian East Asian and Caucasian volunteers. We hypothesize that both 
Cmax and AUC will be higher when rosuvastatin is administered without food when 
compared to fed administration. As rosuvastatin and bile acids share hepatic uptake 
transporters (Ho et al., 2006), we expect that fat content of a co-administered meal will 
affect rosuvastatin pharmacokinetics. Moreover, we hypothesize that bile acids will 
stimulate hepatic entry of rosuvastatin and, since a larger bile-acid load accompanies the 
ingestion of a high-fat meal (Marciani et al., 2013), we expect that plasma rosuvastatin 
AUC will be lowest in the high-fat state. To test this hypothesis, we performed a 
prospective, crossover pharmacokinetic study in 23 healthy Caucasian and East Asian 
volunteers (Section 3.1).  
2.2.2. Specific Aim 2  
Investigate the effect of concomitant food administration with rosuvastatin dose on 
the lipid profiles of statin patients. We hypothesize that there will be greater liver 
retention of rosuvastatin in patients who took their dose with food, even among those 
who appear to have lower systemic statin exposure. We expect that this will be reflected 
as equal LDL-C lowering when compared to individuals who took their rosuvastatin on 
an empty stomach. To test this hypothesis, we retrospectively analyzed data from 157 
previously recruited individuals from the London Health Sciences Centre (LHSC) Lipid 
Clinic (Section 3.2). 
2.2.3. Specific Aim 3  
Determine whether liver-plasma ratios of rosuvastatin are different when an oral 
dose is administered with food compared to a fasted administration. We hypothesize 
that the plasma rosuvastatin AUC and Cmax will be lower and liver rosuvastatin level will 
be higher in a fed state. We expect the liver-to-plasma ratio to be higher when 
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rosuvastatin is administered with food compared to a fasted administration. To test this 
hypothesis, we performed an in vivo pharmacokinetic study in wild-type C57BL/6 mice 
(Section 3.3). 
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3. METHODS  
3.1. Human Pharmacokinetic Study  
3.1.1. Study Design  
A prospective, open, randomized, crossover pharmacokinetic study performed in healthy 
Caucasian and East Asian volunteers was conducted at the Centre for Clinical 
Investigations and Therapeutics (CCIT), LHSC. All individuals within the East Asian 
cohort were of Chinese or Korean decent (self reported). All participants provided written 
informed consent. The study was approved by the Research Ethics Board of the 
University of Western Ontario, London, Canada (Appendix A). Participants were deemed 
healthy by the study physician upon physical examination, a brief medical history, and 
analysis of routine serum chemistry (including a complete cholesterol profile). Moreover, 
participants were not to be on any prescription or non-prescription medications (with the 
exception of oral contraceptives) within one month prior to and during the study. 
Volunteers deemed healthy were invited back to complete three separate study days 
(approximately 10.5 hours each). Volunteers were asked to fast beginning at 12 am the 
morning of each study day, refrain from alcohol consumption 24 hours prior to each 
study day, and refrain from caffeine consumption on each study day. Furthermore, urine 
pregnancy tests were conducted for female volunteers prior to drug administration on 
each study day. Rosuvastatin (Crestor®), 10 mg, was administered on three separate 
study days with one of three standardized breakfasts: fasting, low-fat (20.8% fat, 10.9% 
protein, 58.1% carbohydrates), or high-fat (46.9% fat, 10.1% protein, 39.91% 
carbohydrates). Details regarding the standardized breakfasts can be found in Table 3.  
The order in which each subject underwent the three study days was randomized, and a 
washout period of one week was required between study days. On each of the three study 
days, 5 mL blood samples were collected into ethylenediaminetetraacetic acid (EDTA) 
tubes prior to drug administration and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hours after 
drug administration (Figure 4). Blood samples were then centrifuged at 4 ºC, 2000 rcf for 
10 min to separate plasma and cellular components. Plasma was aliquoted into 
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corresponding cryovials and stored at -80 ºC. At the beginning of the first study day, an 
additional 5 mL blood sample was collected into an EDTA tube for subsequent DNA 
extraction and genotype analysis; this sample was stored as whole blood at 4 ºC. Subjects 
were provided with a meal of their choosing 5 hours after drug administration; each 
subject was then provided with the same meal for the remaining study days.  
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Table 3.  Meal components for high-fat and low-fat breakfasts. 
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Figure 4.  Human pharmacokinetic study design. Abbreviation: CCIT, Centre for 
Clinical Investigations and Therapeutics.  
!27
3.1.2. Determination of Statin Concentrations  
Plasma rosuvastatin concentrations were determined using an adapted version of a 
previously described LC-MS/MS method (DeGorter et al., 2012b). Standard curve values 
were created using blank human plasma (K2 EDTA, BioreclamationIVT, New York, NY, 
USA) and rosuvastatin-calcium salt (Toronto Research Chemicals, North York, ON, 
Canada). Standard aliquots and plasma samples (100 µL) from each time point were 
mixed with 300 µL acetonitrile containing an internal standard (rosuvastatin-d6, Toronto 
Research Chemicals, North York, ON, Canada) to precipitate any residual proteins. This 
mixture was then centrifuged for 20 minutes at 14000 rpm at 4°C. The supernatant was 
removed and diluted 1:1 in 0.05% formic acid in water. A 50 µL aliquot of each sample 
was then injected through a Vantage triple-quadrupole mass spectrometer attached to a 
TLX2 high-performance liquid chromatography system (Thermo TSQ Vantage, Thermo 
Scientific, Pittsburgh, PA; details in Table 4 and Figure 5). Analytes were separated by 
reverse-phase chromatography (Kintex 5 µm EVO C18 100 Å with guard, 50-3.0 mm, 
Torrance, CA, USA) using gradient elution with 0.05% formic acid in water and 
acetonitrile starting at a ratio of 70:30 with a gradient to a ratio of 10:90 (Agilent 1200, 
Agilent, Santa Clara, CA, USA). The flow rate was set at 0.5 mL/min and the total run 
time for each sample was 6.5 min. The lower limit of quantification for rosuvastatin was 
0.1 ng/ml. Assay bias and precision (coefficient of variation) were 1.1% and 8.0%, 
respectively. 
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Table 4.  Vantage triple-quadrupole mass spectrometer attached to a TLX2 high-
performance liquid chromatography system method settings. 
Parameter Setting 
Run duration 6.50 min
Ionspray voltage (positive ion 
mode) 
+3000 V
Sheath gas 50 Arb.
Ion sweep gas -1 Arb. 
Auxiliary gas 20 Arb. 
Capillary temperature  350°C
Collision pressure 1 mTorr
Column Kintex 5 µ EVO C18 100 Å with guard,  50-3.0 mm   
Rosuvastatin Q1 mass 482.1 
amuQ3 mass 258.2 
amu Collision energy -34 V
Ionization mode  Positive
d-Rosuvastatin Q1 mass 488.0 
amuQ3 mass 264.3 
amu Collision energy -34 V
Ionization mode  Positive
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Figure 5.  Vantage triple-quadrupole mass spectrometer attached to a TLX2 high-
performance liquid chromatography system mobile phase composition and gradient 
method. 
Time Flow (mL/min) A(%) B(%)
0.00 0.5 70.0 30.0
0.50 0.5 70.0 30.0
2.50 0.5 10.0 90.0
4.50 0.5 10.0 90.0
5.25 0.5 70.0 30.0
6.00 0.5 70.0 30.0
6.10 0.5 70.0 30.0
7.10 0.5 70.0 30.0
A = 0.05% formic acid in H20 
B = organic acetonitrile
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3.1.3. Pharmacokinetics and Statistical Analysis  
For each treatment condition, the area under the plasma rosuvastatin concentration-time 
curve from 0 to 10  hours (AUC0-10), AUC extrapolated out to infinity (AUC0-∞), the 
maximum plasma concentration (Cmax), and time of maximum concentration (Tmax) were 
calculated using PKSolver (add-in program for pharmacokinetic and pharmacodynamic 
data analysis in Microsoft Excel). The data were first tested for normality using the 
D’Agostino and Pearson omnibus normality test. Non-normal datasets were log-
transformed before subsequent comparison by one-way ANOVA and Tukey’s multiple 
comparisons test. Moreover, using the combined dataset, AUC0-10, AUC0-∞, Cmax, and 
Tmax for each treatment condition were compared between sexes. For this comparison, 
normally distributed data were compared using an unpaired t-test with equal standard 
deviations, whereas non-parametric data were compared using the Mann-Whitney test. 
All statistical analyses were performed using GraphPad Prism 6 (GraphPad, La Jolla, CA, 
USA). 
3.1.4. DNA Extraction and Genotype Analysis  
DNA was isolated from whole blood samples using the MagNA Pure Compact Nucleic 
Acid Isolation Kit I and MagNA Pure Compact Instrument (Roche, Indianapolis, IN, 
USA). DNA samples were analyzed using TaqMan allelic discrimination assays for the 
following polymorphisms: SLCO1B1 c.388A>G (*1b), SLCO1B1 c.521T>C (*5), 
ABCG2 c.421C>A, and  ABCG2 c.34G>A. Patient DNA was loaded in duplicate into 96-
well plates with Applied Biosystems PCR Master Mix and polymorphism-specific SNP 
Genotyping Assay Mix and the assay was performed using the Applied Biosystems Viia 7 
Real-Time PCR System (Thermo Fisher Scientific, Mississauga, ON, Canada). Analysis 
of TaqMan results and assignment of volunteer genotypes for each analyzed 
polymorphism were completed using Viia 7 software (Thermo Fisher Scientific). 
AUC0-∞ and Cmax values were then compared between variant-allele carriers (both 
heterozygous and homozygous) and wild-type individuals for each SNP. The data were 
tested for normality using the D’Agostino & Pearson omnibus normality test; normally 
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distributed data were compared using an unpaired t-test with equal standard deviations, 
whereas non-parametric data were compared using the Mann-Whitney test. 
3.2. Retrospective Analysis of Patient Data  
3.2.1. Study Design  
The study population included 157 previously recruited individuals from the LHSC Lipid 
Clinic from August 2009 to May 2011 (DeGorter et al., 2013). All patients provided 
informed written consent. Each patient was on daily rosuvastatin therapy at the time of 
enrolment and provided a blood sample as previously described (DeGorter et al., 2013). 
Data collected upon enrolment included daily dose of rosuvastatin, time of sample 
collection, and time since last dose. Plasma concentrations of lathosterol and total 
cholesterol (TC) were measured from the provided blood samples as previously described 
(DeGorter et al., 2013). Clinically measured LDL-C levels were used where possible; if 
LDL-C values were not recorded, these values were obtained using the Friedewald 
equation and clinically recorded HDL-C, TC, and triglyceride values. 
Patients who reported taking their last rosuvastatin dose between 5-9 am (inclusive) or 
5-7 pm (inclusive) were presumed to have taken the medication with food (n=75). 
Patients who reported taking their last rosuvastatin dose at or after 8 pm were presumed 
to have taken the medication without food (n=82). Individuals who reported taking their 
last rosuvastatin dose at alternate times were not included for analysis. Moreover, we 
presumed that these patients were likely to routinely take their rosuvastatin dose under 
similar conditions. 
3.2.2. Statistical Analysis  
The average dose of rosuvastatin was compared between individuals presumed to have 
taken their rusuvastatin with food to those presumed to have taken their dose without 
food. Patients were further categorized based on dose: 5 mg, 10 mg, 20 mg, and 40 mg 
daily rosuvastatin. For each dose, plasma LDL-C (n=146), lathosterol (n=154), and total 
cholesterol (n=154) concentrations were compared between individuals presumed to have 
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taken their last dose with food and those presumed to have taken their last dose without 
food. The data were tested for normality using the D’Agostino & Pearson omnibus 
normality test; normally distributed data were compared using an unpaired t-test with 
equal standard deviations, whereas non-parametric data were compared using the Mann-
Whitney test. 
3.3. Mouse Pharmacokinetic Study  
3.3.1. Study Design  
An in vivo pharmacokinetic study was performed in two groups (fed and fasted) of wild-
type C57BL/6 mice (Jackson Laboratory, Bar Harbour, MA; 10 weeks old; ~26 g; 5 per 
group). The mice were housed in a temperature-controlled environment with a 12 h light/
dark cycle where they received standard murine chow and water ad libitum. Six hours 
prior to drug dosing, all food was removed from the fasting mouse group and the bedding 
was changed to ensure that there was no residual food in the cages. The bedding was also 
changed in the cages of the fed mice. All mice were dosed 10 mg/kg rosuvastatin in 
phosphate buffered saline (total volume of 200 µL) by oral gavage. Approximately 30 µL 
of blood was collected prior to rosuvastatin dose (0 time point), and at 7.5, 15, 30, and 60 
min after drug dosing. All blood was collected using a heparinized pipet after saphenous 
vein puncture. At 120 min after drug dosing, the mice were euthanized by isoflurane and 
the remaining blood was collected into EDTA-containing tubes via cardiac puncture. All 
blood samples were centrifuged at 4 ºC, 2000 rcf for 10 min to separate plasma and 
cellular components. Plasma was aliquoted into corresponding cryovials and stored at -80 
ºC. Livers from all mice were excised postmortem, rinsed in phosphate-buffered saline, 
blotted, and weighed; liver samples were flash frozen in liquid nitrogen and stored at -80 
ºC. This study protocol was approved by the Animal Use Subcommittee of the University 
of Western Ontario, London, Canada (Appendix B). Figure 6 details this study design. 
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Figure 6.  Mouse pharmacokinetic study design. 
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3.3.2. Determination of Statin Concentrations  
Mouse plasma and liver rosuvastatin concentrations were determined using an adapted 
version of the LC-MS/MS method described in Section 3.1.2. In brief, two sets of 
standard curve values were prepared. The first set was used when analyzing plasma 
samples and was prepared using blank mouse plasma (K2 EDTA, BioreclamationIVT, 
New York, NY, USA) and rosuvastatin-calcium salt. The second set of standard curve 
values was used when analyzing liver samples and was prepared using homogenized, 
wild-type, untreated, C57BL/6 liver samples and rosuvastatin calcium salt. Liver samples 
and standards were homogenized 1:1 (weight to volume) in 0.05% formic acid in water. 
Plasma samples and liver homogenate samples (5 µL of each) were precipitated using 20 
µL acetonitrile containing internal standard (rosuvastatin–d6) and centrifuged for 20 min 
at 14000 rpm at 4°C. The supernatant from each sample was then diluted 1:2 in 0.05% 
formic acid in water and analysis was carried out as described in Section 2.1.2. Note 
injection volume was reduced to 30 µL for analysis.  
3.3.3. Pharmacokinetics and Statistical Analysis  
AUC from 0 to 2 hours (AUC0-2), AUC extrapolated out to infinity (AUC0-∞), the 
maximum plasma concentration (Cmax), time of maximum concentration (Tmax), and half-
life (T1/2) were calculated using PKSolver. Pharmacokinetic data from the fed and fasted 
mouse groups were compared using the Mann-Whitney test. Liver-to-plasma ratios were 
calculated by dividing the tissue rosuvastatin concentration by the plasma concentration 
at the final sampling time point (2 hour). Mean plasma rosuvastatin concentrations at 2 
hours, liver rosuvastatin concentrations, and liver-to-plasma ratios were compared 
between fed and fasted mouse groups using the Mann-Whitney test. Statistical analysis 
was performed using GraphPad Prism 6. 
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4. RESULTS  
4.1. Human Pharmacokinetic Study  
4.1.1. Demographic and Recruitment Data  
Healthy Canadian East Asian and Caucasian individuals were recruited to complete a 
pharmacokinetic study investigating the effect of concomitantly administered food on the 
oral pharmacokinetics of rosuvastatin. Data that we collected from 11 individuals was 
used to calculate that a sample size of 20 individuals total would provide 80% power to 
observe a 35% difference in plasma rosuvastatin levels at 95% confidence. In total, 27 
healthy participants were enrolled in this study, and 23 participants completed all three 
study days (Figure 7). Of the 14 Caucasian subjects, 6 males and 5 females completed 
the study, and 3 females were withdrawn before study completion. Thirteen East Asian 
subjects were enrolled; 6 males and 6 females completed all three study days and 1 
female did not complete the study. 
Median age (range) and mean body mass index (BMI) ± SD for the Caucasian cohort 
were 22 (21-59) years and 25.92 ± 3.13 kg/m2 respectively (Table 5). These values were 
slightly lower in the East Asian cohort with a median age of 21 (20-23) years and BMI of 
22.90 ± 4.01 kg/m2 (Table 6). Average total cholesterol, circulating triglycerides, HDL-C, 
and LDL-C were similar between cohorts and average values for each cohort were within 
or near the lipid reference ranges as specified by the London Laboratory Services Group 
(2008). Of note,  average LDL-C ± SD for the Caucasian cohort was 2.58 ± 0.68 mmol/L 
and the reference range for LDL-C is ≤ 2.5 mmol/L. Moreover, average HDL-C values 
were slightly above the 1.3-1.55 mmol/L reference for both cohorts: mean HDL-C ± SD 
was 1.64 ± 0.45 mmol/L for the Caucasian cohort and 1.59 ± 0.27 mmol/L for the East 
Asian cohort. Further details regarding subject demographics can be found in Table 5 and 
Table 6. Note that total cholesterol, triglyceride, HDL-C, and LDL-C values presented in 
these tables were determined by LHSC Core Laboratories as part of the initial serum 
screening process for this study. 
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Table 5.  Demographic characteristics of healthy Caucasian subjects.
Abbreviations: SD, standard deviation; BMI, body mass index; TC, total cholesterol; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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Table 6.  Demographic characteristics of healthy East Asian subjects.
Abbreviations: SD, standard deviation; BMI, body mass index; TC, total cholesterol; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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4.1.2. Pharmacokinetic Analysis  
Although rosuvastatin may be taken with or without food, recent work suggests that 
taking rosuvastatin with food may alter its plasma levels (Li et al., 2009; Baek et al., 
2013). To elucidate the effect of concomitant food administration, and type of meal 
administered on the oral pharmacokinetics of rosuvastatin, we performed a prospective, 
randomized, cross-over study in healthy Caucasian and East Asian volunteers. Volunteers 
completed three separate study days on which they received 10 mg of rosuvastatin 
without food, with a low-fat meal, or with a high-fat meal; blood samples were collected 
over 10 hours and subsequently analyzed by LC-MS/MS. Caucasian (n=11) and East 
Asian (n=12) cohorts were analyzed together as a complete cohort (n=23) and separately 
to investigate ethnicity related differences.  
Within both the Caucasian and East Asian subsets, large inter-individual variation was 
observed with regards to the plasma rosuvastatin concentration vs. time curves (Figures 
8A & B). Within the Caucasian cohort, the coefficient of variation was approximately 
19% for both Cmax and AUC0-10 values when rosuvastatin was administered in a fasted 
state (Figure 8Ai). Greater variation was observed in both fed states with approximately 
45% and 43% variation in Cmax, and 37% and 31% variation in AUC0-10 within the low-
fat and high-fat states, respectively (Figures 8Aii & iii). Within the East Asian cohort, 
fasting variation in Cmax and AUC0-10 were approximately 4-fold larger than 
corresponding values observed within the Caucasian subset (Figure 8Bi). Variation 
within the fed states were also quite high for the East Asian cohort, with approximately 
80% and 60% variation in Cmax, and 87% and 63% variation in AUC0-10 within the low-
fat and high-fat states, respectively (Figures 8Bii & iii). These data suggest that extent of 
variation in rosuvastatin levels may be dependent on ethnic differences. 
Similar to previous reports, we observed a mean Tmax for rosuvastatin around 4 hours 
within the Caucasian cohort (DeGorter et al., 2012b) (Table 7). The time to maximum 
concentration of rosuvastatin remained consistent throughout the fasted and fed states. 
Plasma rosuvastatin concentrations from 0 to 10 hours post dose for healthy Caucasian 
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individuals are displayed in Figure 9A. Within the Caucasian subset of volunteers, 
plasma rosuvastatin Cmax, AUC0-10, and AUC0-∞, were significantly higher (p<0.001, 
p<0.0001, and P<0.0001 respectively) when rosuvastatin was administered without food 
compared to administration with a low-fat meal (Table 7, Figure 9B). Similarly, 
rosuvastatin Cmax, AUC0-10, and AUC0-∞, were significantly higher (p<0.05, p<0.001, and 
p<0.001 respectively) when rosuvastatin was administered without food compared to 
administration with a high-fat meal (Table 7, Figure 9B). Lower systemic levels when 
rosuvastatin is administered with a meal suggests that food either impairs intestinal 
absorption or augments hepatic clearance of rosuvastatin. No significant differences in 
plasma rosuvastatin levels were observed between the low-fat and high-fat states (Table 
7, Figures 9A & B).  
Within the East Asian cohort, mean Tmax was approximately 1.5 and 1.4-fold longer when 
rosuvastatin was administered with a low-fat and high-fat meal, respectively, when 
compared to administration without food (p<0.05 for both; Table 7). This indicates that 
within this population, the presence of food delayed the intestinal absorption of 
rosuvastatin. No significant differences were found in plasma Cmax, AUC0-10, or AUC0-∞, 
among the fasting, low-fat, or high-fat states (Table 7, Figures 9C & D). However, 
plasma rosuvastatin levels (Cmax, AUC0-10, and AUC0-∞) were approximately 1.8 and 1.4-
fold lower when rosuvastatin was administered with a low-fat and a high-fat meal, 
respectively, when compared to levels attained under fasted conditions (Table 7, Figures 
9C & D). This suggests that within this population, a food effect may be masked by large 
inter-individual variability. 
Within the combined dataset (including both Caucasian and East Asian volunteers), Cmax, 
AUC0-10, and AUC0-∞, were significantly higher (p<0.01, p<0.01, and p<0.05 
respectively) when rosuvastatin was administered without food compared to 
administration with a low-fat meal (Table 7, Figures 9E & F). Additionally, Tmax was 
significantly longer (p<0.05) when rosuvastatin was administered with a low-fat meal 
compared to a fasted administration (Table 7). No significant differences were observed 
when the pharmacokinetic parameters from the high-fat state were compared to those 
!41
observed in the fasting or low-fat states (Table 7, Figure 9E & F). Moreover, no sex-
related differences in AUC0-10, AUC0-∞, Cmax, or Tmax were found (data not shown), which 
is consistent with previous reports (Martin et al., 2002).  
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4.1.3. Pharmacogenetic Analysis  
Previously, DeGorter et al. (2013) assessed the association of clinical PGx variables with 
the plasma rosuvastatin levels observed in a cohort of 130 rosuvastatin patients. After 
adjustment for age, ethnicity, body mass index, sex, dose, and time from last dose, 
Degorter et al. determined that plasma rosuvastatin concentrations were higher in 
individuals with variant alleles for SLCO1B1 c.521T>C and/or ABCG2 c.421C>A. 
Additionally, SLCO1B1 c.388A>G and ABCG2 c.34G>A have been associated with 
altered statin pharmacokinetics (Maeda et al., 2006; Tornio et al., 2015; Wan et al., 
2015). Here we analyzed these four genotypes within this population of healthy 
Caucasian (n=11) and East Asian volunteers (n=12). 
Reported allele frequencies for SLCO1B1 c.521T>C are around 15%, with similar 
frequencies detected within Caucasian and Asian populations. However, frequencies for 
SLCO1B1 c.388A>G range from approximately 30-45% in Caucasian populations to 
60-90% in Asian populations (Pasanen et al., 2008). In our cohort, c.521T>C and c.
388A>G frequencies were approximately 18% and 59% respectively for the Caucasian 
subset of volunteers. Within the East Asian subset, allelic frequencies for c.521T>C and 
c.388A>G were approximately 4% and 67%, respectively. Both ABCG2 c.421C>A and c.
34G>A have been found in Caucasian populations at frequencies <15%. In Asian 
populations, allelic frequencies for c.421C>A and c.34G>A are more common and have 
been reported as approximately 15-35% and 15-45%, respectively (Yasuda et al., 2008). 
Within this population, c.421C>A was not detected in the Caucasian subset and had an 
allelic frequency of approximately 42% in the East Asian subset. Allele frequencies for c.
34G>A were approximately 5% in the Caucasian subset and 38% in the East Asian subset 
of volunteers. Genotypes for all 23 volunteers are presented in Table 8.  
To examine the impact of genotype on maximum rosuvastatin concentration and systemic 
exposure within this population, we compared plasma Cmax and AUC0-∞ values between 
wild-type individuals and carriers of a particular variant allele. For this analysis, 
heterozygous and homozygous variant carriers were combined. Moreover, because food 
!46
appears to affect plasma rosuvastatin concentrations, analysis was carried out using Cmax 
and AUC0-∞ values measured when a 10 mg oral dose of rosuvastatin was given directly 
following a high-fat meal, a low-fat meal, and in the absence of food. Within the fasted 
state, carriers of ABCG2 c.421A had a 3.6-fold higher mean Cmax and 3.5-fold higher 
mean AUC0-∞ when compared to non-carriers (Figures 10A & B). No significant 
differences between mean Cmax or AUC0-∞ were found between wild-type individuals  and 
variant carriers of SLCO1B1 c.521T>C, SLCO1B1 c.388A>G, or ABCG2 c.34G>A 
(Figure 10). Within the high-fat and low-fat states, carriers of ABCG2 c.421A had an 
approximate 3-fold higher mean Cmax when compared to non-carriers (Figures 11A & 
12A). Similarly, mean AUC0-∞ was approximately 4-fold greater for ABCG2 c.421 variant 
carriers when compared to wild-type individuals within both fed states (Figures 11B & 
12B). No significant differences between mean Cmax or AUC0-∞ were found between wild-
type individuals and variant carriers of SLCO1B1 c.521T>C, SLCO1B1 c.388A>G, or 
ABCG2 c.34G>A for either of the fed states (Figures 11 & 12). 
Within this population, all ABCG2 c.421C>A variant carriers were of East Asian descent. 
Moreover, rosuvastatin Cmax and AUC0-∞ levels were, on average, higher within the East 
Asian cohort when compared to levels found within the Caucasian cohort. Therefore, to 
ensure that the correlation between ABCG2 c.421A and plasma rosuvastatin levels was 
not biased by ethnicity differences, ABCG2 c.421C>A was assessed in the East Asian 
cohort separate from the Caucasian cohort. Within the fasted state, mean Cmax was 
approximately 2-fold higher and mean AUC0-∞ was approximately 3-fold higher in 
variant-allele carriers when compared to non-carriers; however, these  differences were 
not significant (Figure 13A). Within the low-fat state, variant carriers had significantly 
higher mean Cmax (p=0.008) and AUC0-∞ (p=0.004) when compared to non-carriers 
(Figure 13B). Similarly, mean Cmax (p=0.008) and AUC0-∞ (p=0.008) were significantly 
higher for variant carriers when compared to wild-type individuals (Figure 13C). 
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Table 8.  Genotypes of healthy Caucasian and East Asian volunteers.  
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Figure 13.  Effect of ABCG2 c.421C>A on rosuvastatin maximum concentration 
(Cmax) and B. area under the plasma concentration-time curve extrapolated out to 
infinity (AUC0-∞) in healthy East Asian (n=12) individuals administered 10 mg oral 
rosuvastatin (A) without food, (B) with a low-fat meal, and (C) with a high-fat meal. 
Top and bottom of the boxes represent the 25th and 75th percentile, respectively; the line 
between these represents the median. The whiskers depict the 5th and 95th percentile. 
Significance of the mean difference between variant carriers (n=8) and wild-type (WT; 
n=4) individuals is depicted as  **p<0.01. 
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4.2. Retrospective Analysis of Patient Data  
To investigate the effect of concomitant food administration with rosuvastatin dose on the 
lipid profiles of statin patients, we analyzed data from 157 previously recruited 
individuals from the LHSC Lipid Clinic. Upon enrolment, a blood sample was collected 
and the daily dose of rosuvastatin, time of sample collection, and time since last dose 
were recorded (DeGorter et al., 2013). Patients that reported taking their last rosuvastatin 
dose between 5-9 am (inclusive) or 5-7 pm (inclusive) were presumed to have taken the 
medication with food (n=75). Patients that reported taking their last rosuvastatin dose at 
or after 8 pm were presumed to have taken the medication without food (n=82). 
Moreover, because patients tend to take their medications at the same time every day, we 
presumed that this data would reflect the daily administration habits of these patients.  
Within both populations, the majority of patients were Caucasian males. Median age 
(range) and BMI ± SD for the cohort of individuals presumed to take their rosuvastatin 
with food were 59.0 (19-80) years and 29.9 ± 5.9 kg/m2 respectively. In the cohort of 
individuals presumed to take their rosuvastatin without food the median age (range) and 
BMI ± SD were 58.5 (23-90) years and 30.7 ± 7.6 kg/m2 respectively. The average 
number of concomitant medications ± SD taken by patients presumed to take their 
rosuvastatin with and without food were 6.4 ± 3.2 and 6.3 ± 3.5 respectively. Further 
details regarding population characteristics can be found in Table 9.  
Rosuvastatin targets the liver and effectively reduces plasma concentrations of LDL-C. 
Patients of the LHSC Lipid Clinic have their rosuvastatin doses adjusted so that their 
LDL-C values fall within a defined range. Within this study population, the average dose 
of rosuvastatin was not significantly different between individuals presumed to take 
rosuvastatin with or without food (Figure 14). This indicates that in this population, 
taking rosuvastatin with or without food did not affect its capacity to lower LDL-C.  
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We further divided the cohorts by dose and compared plasma concentrations of LDL-C, 
total cholesterol, and lathosterol, a cholesterol biosynthesis intermediate. Taking 
rosuvastatin with or without food did not significantly affect average LDL-C or 
lathosterol concentrations for individuals taking a daily 5 mg, 10 mg, 20 mg, or 40 mg 
rosuvastatin dose (Figure 15A and 15C). At a dose of 5 mg of rosuvastatin, total 
cholesterol was found to be significantly lower (p=0.032) in patients that took their dose 
with food compared to those that took their dose without food (Figure 15B). However, at 
10 mg, 20 mg, and 40 mg, no significant differences in average total cholesterol were 
found between individuals presumed to take their rosuvastatin dose with or without food 
(Figure 15B). Together, these results indicate that taking rosuvastatin with or without 
food does not alter the amount of rosuvastatin that reaches the liver and thus does not 
affect the ability of rosuvastatin to inhibit endogenous cholesterol production. 
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Table 9.  Characteristics of London Health Sciences Centre lipid clinic patients 
taking rosuvastatin once daily with or without food.  
Data are presented as % or mean (SD).
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Figure 14.  Average dose of rosuvastatin taken by London Health Sciences Centre 
lipid clinic patients presumed to take their dose with (n=75) or without (n=82) food. 
Data are presented as mean + SD.  
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Figure 15.  Average (A) low-density lipoprotein cholesterol (n=146), (B) total 
cholesterol (n=154), and (C) lathosterol (n=154) concentrations in London Health 
Sciences Centre lipid clinic patients presumed to take rosuvastatin with or without 
food. The data are divided by dose of daily rosuvastatin and are presented as mean + SD. 
Lipid parameter values were compared at each dose and significance is depicted by 
*p<0.05.  
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4.3. Mouse Pharmacokinetic Study  
Taking rosuvastatin with food has been shown to result in lower drug plasma levels when 
compared to those achieved from a fasted administration (Li et al., 2009; Baek et al., 
2013). This may be due to either decreased intestinal absorption or increased hepatic 
clearance of rosuvastatin in the presence of food. To further investigate a potential food 
effect, we performed a pharmacokinetic study whereby 10 mg/kg of rosuvastatin was 
administered via oral gavage to fed and fasted wild-type C57BL/6 mice. Previous data 
from our laboratory examining rosuvastatin pharmacokinetics after oral administration in 
wild-type C57BL/6 mice showed that the mean plasma AUC0-∞ was approximately 127.6 
ng*h/mL with a standard deviation of 23.2 (n=6; Knauer, 2012). Using this data, we 
calculated that a sample size of n=5 per group would provide 80% power to observe a 
30% difference in plasma rosuvastatin levels at 95% confidence. One mouse was 
excluded as an outlier because its Cmax and AUC values were 9-fold greater than the 
average values within the same group. Data from n=4 fed mice and n=5 fasted mice were 
analyzed. 
Comparable to earlier reports, we found the oral absorption of rosuvastatin to be quite 
rapid (Peng et al., 2009; Knauer, 2012). The highest rosuvastatin plasma concentrations 
were observed at the the first time point (7.5 min) for both fed and fasted mice (Figure 
16). Half-life of rosuvastatin was not significantly different between fed and fasted mice 
(Table 10). Analysis of mean values for Cmax, AUC0-2, and AUC0-∞ revealed an 
approximate 2.7, 2.8, and 2.4 respective fold increase when rosuvastatin was given under 
fasted conditions compared to a fed administration. However, due to large inter-mouse 
variation, no significant differences were found in Cmax, AUC0-2, or AUC0-∞ between fed 
and fasted mice (Table 10). These results would suggest that food does not significantly 
affect the oral pharmacokinetics of rosuvastatin in this mouse model; however, it is 
possible that large inter-mouse variability is masking an underlying effect.  
The liver-to-plasma concentration ratio of a medication is a sensitive marker of its hepatic 
uptake. Therefore, to investigate hepatic transport of rosuvastatin in response to food 
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intake, we measured the terminal plasma concentration, liver concentration, and liver-to-
plasma concentration ratio of rosuvastatin in our fed and fasted mice. At the terminal time 
point (2 hours), the average plasma rosuvastatin concentration was significantly greater 
(p=0.0159) for fasted mice when compared to fed mice (Figure 17A). However, liver 
concentrations of rosuvastatin were not significantly different (p=0.2857) between fed 
and fasted mice (Figure 17B). Mean liver-to-plasma concentration ratio of rosuvastatin 
was 2.1-fold greater in fed mice when compared to fasted mice, however these values 
were not significantly different (p=0.1905; Figure 17C). Taken together, these results 
suggest that in this mouse model, hepatic uptake of rosuvastatin is not altered by the 
presence of food. However, higher 2 hour plasma concentrations in fasted mice and an 
approximate 2-fold increase in liver-to-plasma concentration ratio in fed mice when 
compared to fasted mice indicates that an effect may be masked by large inter-mouse 
variability.  
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Figure 16.  Plasma concentration-time curves of rosuvastatin in fed (n=4) and fasted 
(n=5) C57BL/6 mice after administration of 10 mg/kg rosuvastatin via oral gavage. 
Plasma was collected from blood samples taken at 7.5, 15, 30, 60, and 120 min post dose. 
Plasma rosuvastatin concentrations were measured by LC-MS/MS. Data are presented as 
mean + SD.  
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Table 10.  Analysis of pharmacokinetic parameters in fed and fasted wild-type 
C57BL/6 mice after administration of 10 mg/kg rosuvastatin via oral gavage. 
 
Data are presented as mean (SD).
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Figure 17.  Rosuvastatin concentrations in (A) plasma, (B) liver, and (C) the liver-to-
plasma concentration ratio in fed (n=4) and fasted (n=5) C57BL/6 mice 2 hours after 
a 10 mg/kg oral rosuvastatin dose. Plasma was collected from blood samples taken at 2 
hours post dose. Livers were excised 2 hours post dose and later homogenized. 
Rosuvastatin concentrations in the plasma and liver homogenate samples were measured 
by LC-MS/MS. Data presented as mean with SD. Significance of the mean difference 
between fed and fasted mice is depicted by *p<0.05.  
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5. SUMMARY & DISCUSSION  
Statin medications are first-line pharmacotherapy for the treatment of 
hypercholesterolemia and prevention of cardiovascular disease, and an estimated 25.2 
million Americans are currently receiving statin therapy (Pencina et al., 2014). Statins 
function through targeted accumulation within the liver and inhibit the rate-limiting 
enzyme in cholesterol biosynthesis, HMG-CoA reductase (Ho et al., 2006). High 
circulating levels of statins have been associated with a number of statin-induced adverse 
events (Golomb & Evans, 2008). Indeed, muscle pain or weakness occurs in up to 10% of 
statin patients and is a frequent cause of discontinuation of statin therapy (Joy & Hegele, 
2009; Abd & Jacobson, 2011). Observed inter-individual variation in plasma statin 
exposure in patients is associated, in part, with polymorphisms within hepatic uptake and 
efflux transporters such as OATP1B1 and the efflux transporter BCRP. However, given 
the 45-fold or higher variability in plasma statin levels between patients on the same daily 
dose (DeGorter et al., 2013), it is clear that known genetic polymorphisms in statin 
disposition pathways do not adequately account for all variation in statin exposure, 
suggesting that additional pathways or mechanisms may be involved. Interestingly, taking 
medications with food has the potential to alter the physiochemical properties of the drug, 
and/or change the pharmacokinetic or pharmacodynamic profiles of the drug, thus 
leading to variation in plasma exposure (Singh, 1999). 
Significant evidence indicates that plasma levels of commonly prescribed statins, such as 
pravastatin and atorvastatin, are lower when administered with food compared to a fasted 
administration (Pan et al., 1993; Radulovic et al., 1995). Currently, there is conflicting 
evidence regarding the effect of food on plasma rosuvastatin levels. The approval 
package for Crestor® (rosuvastatin calcium) suggests that food does not alter rosuvastatin 
systemic exposure (Center for Drug Evaluation and Research, 2012). However, a study 
performed in healthy Chinese subjects indicated a profound decrease in rosuvastatin 
plasma levels (both Cmax and AUC) when rosuvastatin was administered with food (Li et 
al., 2009).  
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A primary objective of this study was to investigate the effect of concomitantly 
administered meals (both high-fat and low-fat meals) on plasma rosuvastatin 
concentrations in healthy Canadian East Asian and Caucasian volunteers. We 
demonstrated for the first time that concomitant administration with food substantially 
reduced mean plasma rosuvastatin Cmax and AUC in healthy Caucasian and East Asian 
subjects. We found that within healthy Caucasian individuals administering 10 mg oral 
rosuvastatin with a low-fat or high-fat meal resulted in an average reduction in mean 
plasma rosuvastatin levels (average of Cmax, AUC0-10, and AUC0-∞) of approximately 46% 
and 35%, respectively when compared to values observed under fasting conditions. We 
found similar reductions of approximately 45% and 31%, for the low-fat and high-fat 
states respectively, in an East Asian cohort. Similarly, within mice we observed 
considerably lower AUC values when 10 mg/kg rosuvastatin was administered orally to 
fed mice when compared to fasted mice. However, in part due to sample size and marked 
variation between mice, this difference was not found to be significant.  
Previously, Li et al. (2009) found that administering 10 mg oral rosuvastatin to healthy 
Chinese subjects directly following a large meal resulted in >90% decrease in mean AUC 
and Cmax values when compared to fasting values. Li et al. used generic rosuvastatin 
provided by DYNE PHARMA, a manufacturer in Shandong, China. Formulation 
differences between these tablets and the Crestor® tablets used in our study may account 
for the difference in the magnitude of the response to food. Moreover, the test meal used 
by Li et al. was larger than either of the treatment breakfasts used in our study and 
consisted of  approximately 1046 kcal and 43 g of fat compared to 712 kcal and 37 g for 
the high-fat meal and 661 kcal and 15 g for the low-fat meal used in our study. 
Administration of a larger test meal may also help to explain the difference in the 
magnitude of the response to food between the two studies. Similar to Li et al., we found 
that administration with food significantly increased time to maximum rosuvastatin 
concentration within our East Asian cohort. Interestingly, we did not observe this effect 
within our Caucasian cohort, suggesting ethnic differences in the response to food. 
!64
Although the overall percent reduction in rosuvastatin systemic exposure was similar 
between Caucasian and East Asian subjects. 
Similar to Li et al., we observed the overall effect of reduced rosuvastatin exposure when 
it is taken with food compared to administration without food. Li et al. concluded that 
rosuvastatin systemic exposure was likely lower when administered with food due to 
impaired intestinal absorption. However, lower systemic exposure could also be 
explained by increased hepatic uptake and clearance of rosuvastatin in the presence of 
food. To investigate the contribution of hepatic uptake of rosuvastatin in the presence of 
food, we administered 10 mg/kg of rosuvastatin to fed and fasted mice and then 
compared their plasma and liver drug concentrations 2 hours post dose. We observed 
significantly higher plasma rosuvastatin concentrations at the terminal time point in 
fasted mice when compared to fed mice. Moreover, we observed no significant difference 
in the liver concentrations of rosuvastatin between the fed and fasted mice. The liver-to-
plasma concentration ratio of a medication is a sensitive marker of its hepatic uptake. 
Within mice, mean liver-to-plasma concentration ratio was approximately 2.1-fold higher 
in fed mice when compared to fasted mice administered oral rosuvastatin, although this 
difference was not significant. We observed rather large inter-mouse variability in 
rosuvastatin levels and are unable to confirm differences in hepatic uptake of rosuavstatin 
when it is administered to fed and fasted mice. Importantly, as this work was performed 
in mice, it may not be truly reflective of what occurs in humans.  
Although the OATP family of transporters has been viewed as the principal mediators for 
the hepatic uptake of statins, previous data in our lab demonstrates that liver-specific 
NTCP may account for nearly one third of rosuvastatin uptake (Ho et al., 2006). 
Increased expression or activity of NTCP would, therefore, aid in clearance of 
rosuvastatin from portal circulation, while lowering circulating statin concentrations. 
NTCP is a major transporter involved the enterohepatic recirculation of bile acids, and its 
expression and activity are highly regulated to allow for efficient management of a high 
bile-acid load associated with food ingestion (Anwer & Stieger, 2014). Since a larger 
bile-acid load accompanies the ingestion of a high-fat meal (Marciani et al., 2013), we 
!65
hypothesized that plasma rosuvastatin levels would be lowest when a rosuvastatin dose 
was administered with a high-fat meal. Indeed, Baek et al. (2013) found that Cmax and 
AUC of rosuvastatin were significantly lower when a 10 mg oral dose was administered 
to dogs fed a high-fat meal when compared to those fed a low-fat meal prior to dosing. 
Interestingly, we did not observe any significant differences in Cmax or AUC values when 
rosuvastatin was administered following a high-fat compared to administration following 
a low-fat meal within our healthy human cohorts. This disparity may, in part, be 
explained by differences in gastrointestinal physiology and biochemistry and/or 
variability in expression of important hepatobiliary transporters between humans and 
dogs (Kararli, 1995; Wang et al., 2015). Moreover, it is possible that the difference in fat 
content between the high-fat and low-fat breakfasts used in the present study was not 
large enough to detect a difference with respect to an effect on rosuvastatin 
pharmacokinetics in humans.  
Efficacy of statin-mediated HMG-CoA reductase inhibition is often determined through 
measuring reductions in LDL-C or lathosterol, a late intermediate in cholesterol 
biosynthesis. Previous work has shown that LDL-C reductions were not significantly 
different in healthy volunteers following administration of 10 mg atorvastatin tablets with 
or without food for 15 days (Whitfield et al., 2000). Similarly, taking pravastatin or 
fluvastatin with or without food did not significantly affect their LDL-C lowering 
capacities (Pan et al., 1993; Dujovne & Davidson, 1994). In the present study we 
determined that mean plasma levels of LDL-C and lathosterol were not significantly 
different in LHSC Lipid Clinic patients presumed to take their daily rosuvastatin dose 
with or without food. This finding itself is not wholly surprising, as LHSC Lipid Clinic 
patients have their rosuvastatin doses titrated to effect. However, we also found that the 
average dose of rosuvastatin was not significantly different between patients presumed to 
take their rosuvastatin with or without food. These results suggest that taking rosuvastatin 
with or without food does not significantly affect the amount of rosuvastatin that reaches 
the liver to inhibit endogenous cholesterol production. Taken together, results from the 
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present work indicate that taking rosuvastatin with food results in lower rosuvastatin 
systemic exposure but does not likely affect its therapeutic actions. 
A significant impediment to statin therapy is muscle toxicity resulting from high systemic 
statin exposure (DeGorter et al., 2013). Statin-induced muscle toxicities most commonly 
present as muscle pain or weakness known as myalgia, occurring in up to 10% of statin 
patients (Joy & Hegele, 2009). Infrequently, a life-threatening form of muscle toxicity, 
rhabdomyolysis, may occur as a result of statin therapy (Polderman, 2004). Switching 
statins to avoid statin-induced muscle toxicities may be efficacious. Indeed, one study 
reported that 43% of patients that had switched to another statin after an episode of statin-
induced myopathy did not experience recurrent symptoms (Hansen et al., 2005). 
However, it is unclear what effect switching statins had on LDL-C reduction within these 
patients. Changing a patient’s dosing schedule from daily to alternate-day dosing has also 
been suggested as a means to mitigate statin-induced myalgia (Joy & Hegele, 2009), 
however statin efficacy may suffer from such an approach. For example, Dulay et al. 
(2009) observed LDL-C reductions of 48.5% in hypercholesterolemic patients taking 10 
mg rosuvastatin daily, versus 40.9% when a 20 mg dose of rosuvastatin was given on 
alternate days. Even small changes in LDL-C reduction can have a profound impact on 
patient outcome. For example, data from a large meta-analysis by the Cholesterol 
Treatment Trialists’ Collaborators (2005) indicated that a 1 mmol/L reduction in LDL-C 
that is sustained for 5 years would likely produce a 23% reduction in major vascular 
events. The present work suggests that taking rosuvastatin with food lowers systemic 
exposure of rosuvastatin without compromising LDL-C reduction. Therefore, patients 
may find that taking rosuvastatin with food may prove to be a meaningful strategy for 
maintaining statin efficacy while mitigating statin-induced muscle adverse effects.  
Statins are commonly prescribed to both men and women for the treatment of 
hyperlipidemia. Although the pharmacokinetic profiles of rosuvastatin are similar in men 
and women (Martin et al., 2002), studies investigating other statin medications have 
reported sex-related differences in statin systemic exposure (Gibson et al., 1996; Cheng 
et al., 1992). In this work, we demonstrated that the effect of food on the oral 
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pharmacokinetics of rosuvastatin is similar between Caucasian and East Asian men and 
women. However, female gender has been associated with an approximate 2-fold 
increase in statin-induced myopathy risk (Feng et al., 2012). Taking rosuvastatin with 
food may, therefore, prove to be a particularly important strategy for reducing statin-
induced myopathy risk within female rosuvastatin patients. Other risk factors for 
developing statin-induced myopathy where individuals may similarly benefit from a 
change in rosuvastatin administration behaviour include a history of myopathy, advanced 
age, high-dose statin therapy, concomitant use of medications known to increase statin 
systemic exposure, or carriers of select genetic mutations (Joy & Hegele, 2009). 
BCRP is an efflux transporter, coded for by ABCG2, which plays an important role in the 
disposition of rosuvastatin (DeGorter et al., 2012c). ABCG2 c.421C>A has been 
associated with higher plasma rosuvastatin concentrations in healthy volunteers 
(Keskitalo et al., 2009b). Moreover, in Chinese patients being treated with 10 mg of 
rosuvastatin daily, homozygous variant carriers of ABCG2 c.421C>A showed a 6.9% 
greater reduction in LDL-C level when compared to homozygous wild-type individuals 
(Tomlinson et al., 2010). Higher allelic frequencies of ABCG2 c.421C>A in Asian 
populations when compared to Caucasian populations may explain the higher plasma 
rosuvastatin levels previously reported within Asian subjects when compared to 
Caucasian subjects (Yasuda et al., 2008; Lee et al., 2005). Increased plasma levels of 
rosuvastatin may predispose Asian patients to severe myopathy. Consequently, the daily 
maximum approved dose in Asian countries is 20 mg compared with 40 mg within North 
America (DeGorter et al., 2013). In this study, ABCG2 c.421C>A allele frequency was 
much higher in our East Asian cohort when compared to the Caucasian cohort. 
Furthermore, we found that carriers of ABCG2 c.421C>A had higher rosuvastatin Cmax 
and AUC0-∞ values when compared to non-carriers and that this effect was independent of 
food administration with rosuvastatin. Taken together, our findings suggest that carriers 
of ABCG2 c.421C>A that take their rosuvastatin dose without food may be at an 
increased risk for high plasma exposure of rosuvastatin and, consequently, developing 
statin-induced myopathy. Of note, we investigated other SNPs within ABCG2 and 
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SLCO1B1 but did not observe any differences with regards to plasma rosuvastatin 
concentrations between variant carriers and non-carriers. 
5.1. Conclusions  
In this study we investigated the effect of concomitant food administration on plasma 
rosuvastatin concentrations in healthy Canadian East Asian and Caucasian volunteers. We 
also sought to determine whether LHSC lipid clinic patients who took their rosuvastatin 
dose with food had altered lipid profiles when compared to those that took their dose 
without food. Finally, we investigated a potential food effect on the plasma and liver 
levels of rosuvastatin within wild-type C57BL/6 mice. Taken together, these studies 
provide insight into the effect of food on the oral pharmacokinetics of rosuvastatin.  
Conflicting evidence existed with regards to a potential effect of concomitant food 
administration on plasma rosuvastatin exposure. Through our work in healthy Caucasian 
and East Asian volunteers and within mice, it is apparent that taking rosuvastatin with 
food alters its oral pharmacokinetics. Our findings support our previous hypothesis that 
taking rosuvastatin with food results in lower circulating statin levels. Moreover, the 
findings from our retrospective analysis of lipid data collected from rosuvastatin patients 
indicates that taking rosuvastatin with or without food does not affect its LDL-cholesterol 
lowering capacity.  
Statin-induced muscle pain is a major reason for discontinuation of therapy (Abd & 
Jacobson, 2011). Muscle toxicity is often associated with high statin dose and increased 
statin plasma exposure (Jacobson, 2006). Here we demonstrate that taking rosuvastatin 
with food results in lower systemic exposure without compromising its therapeutic 
benefit. Therefore, our findings have the potential to serve as a novel and simple strategy 
for mitigating statin myopathy risk. Furthermore, we revealed that carriers of ABCG2 c.
421C>A variant allele have higher plasma levels of rosuvastatin when compared to non-
carriers. The risk of excessive rosuvastatin systemic exposure and, consequently, risk of 
myopathy might be greatest in ABCG2 c.421C>A variant carriers that consistently take 
their rosuavsatatin dose without food. 
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Current United States and Canadian dosing guidelines indicate no preference for fed or 
fasted rosuvastatin administration (Center for Drug Evaluation and Research, 2012). The 
findings from this work indicate that a modification to these guidelines should be 
considered, suggesting that rosuvastatin patients take their dose with a meal. Moreover, 
this modification to the administration guidelines may be particularly important for 
individuals required to be on high-dose rosuvastatin to meet therapeutic target or for 
carriers of the ABCG2 c.421C>A variant allele. 
5.2. Limitations  
The FDA recognized the potential for food to alter the oral pharmacokinetics of new 
medications and established guidelines for the design of clinical food-effect studies. The 
FDA Guidance on Food-Effect Bioavailability and Fed Bioequivalence Studies 
recommends that medications be administered under fasted and fed conditions, where the 
fed state consists of a meal around 1000 calories (approximately 50% from fat) in order 
to maximize the prospects for an observable food effect (Food and Drug Administration, 
2002). Neither the low-fat or high-fat meals used within the healthy-volunteer PK study 
section of this work meet these standards. It is possible that had the test meals been 
designed to meet the standards proposed by the FDA guidance, a larger food effect could 
have been demonstrated. However, in designing the test meals for this work, we sought 
guidance from LHSC dieticians and chose items that are not contraindicated in 
hyperlipidemic patients. Therefore, we suspect that the magnitude of the rosuvastatin-
food effect found within our healthy Caucasian and East Asian cohorts more closely 
resembles that which would be found within statin patients.  
In order to investigate the effect of concomitant food administration with rosuvastatin 
dose on the lipid profiles of statin patients, we made a number of assumptions regarding 
the administration behaviours of LHSC lipid clinic patients. First, we used a patient’s 
time since last rosuvastatin dose to infer whether or not they likely took the dose with 
food. We assumed that individuals who reported taking their last dose between 5-9 am 
(inclusive) likely did so with breakfast, and those who reported taking their dose between 
5-7 pm (inclusive) likely did so with dinner. Furthermore, we presumed that individuals 
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who reported taking their last dose after 8 pm likely did so before bed and without food. 
Next, we assumed that patients were likely to routinely take their rosuvastatin dose under 
similar  conditions.  Although  we  recognize  that  these  classifications  are  unlikely  to 
encompass  all  individuals,  we  believe  them to  be  fair  estimates  as  patients  (through 
physician encouragement) tend to link drug doses to aspects of their daily routine such as 
meal times or before bed (Crammer, 1998). Moreover, the retrospective analysis of LHSC 
lipid clinic patient data was conducted in a predominantly Caucasian population,  and 
caution should be used when extrapolating these findings to other ethnicities. 
We further examined the effect of food on the oral pharmacokinetics of rosuvastatin in 
wild-type C57BL/6 mice. We used previously collected data from our lab in order to 
calculate an appropriate sample size of 5 mice per group. The variance in plasma 
rosuvastatin levels within our mice was larger than expected and, therefore, this work 
would have benefitted from a larger sample size. Moreover, a potential food effect was 
assessed by fasting one group of mice for 6 hours prior to drug administration and 
comparing their plasma levels of rosuvastatin to levels collected from non-fasted mice. 
Lights were left off during the 6 hour fasting period to promote the normal nocturnal 
feeding patterns within the mice that had access to food. However, we did not verify if or 
when these mice consumed the food.  
5.3. Future Directions  
Both our work and the work done by Li et al. (2009), investigate the effect of food on 
rosuvastatin oral pharmacokinetics in young (average ages between 21-29 years), healthy 
volunteers. An important follow-up study to the work presented in this thesis would be to 
investigate the effect of food on rosuvastatin pharmacokinetics prospectively in statin-
treated dyslipidemic patients. Specifically, one could design a study whereby 
rosuvastatin-treated patients are asked to take their dose with a large meal everyday for 
two weeks and then complete a one-day PK study. The patient could then be asked to 
switch administration behaviours and begin taking their rosuvastatin dose before bed 
without food for two weeks and then once again complete a one-day PK study. 
Alternatively, previous work from our lab has identified 5 hours post dose as the single 
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time point where blood sampling best correlates with rosuvastatin AUC0-10 (DeGorter et 
al., 2012b), thus a full PK study may not be necessary. Lipid parameters such as LDL-C 
and lathosterol should be determined from blood samples collected at the end of each 
two-week period. Rosuvastatin plasma levels and lipid parameters could then be 
compared between administration methods. Moreover, it may be helpful to survey any 
changes in muscle fatigue or discomfort throughout the study period. Care should be 
taken when implementing such a study design in patients on a high dose of rosuvastatin 
or ABCG2 c.421C>A variant-allele carriers.  
In this work, we found that administering an oral dose of rosuvastatin to fed mice resulted 
in lower plasma statin concentrations when compared to values obtained within fasted 
mice. Moreover, the mean liver-to-plasma concentration ratio was approximately 2.1-fold 
greater in fed mice when compared to fasted mice, but this difference was not significant. 
Detecting a significantly higher mean liver-to-plasma concentration ratio within the fed 
mice would provide support for the hypothesis that administering rosuvastatin with food 
results in enhanced hepatic disposition. A future study with a larger sample size may 
provide better insight into a potential mechanism for the observed food effect. 
Furthermore, dogs have been identified as the most appropriate animal model for 
understanding or predicting the effect of food on drug pharmacokinetics within humans, 
and a study investigating the effects of food on rosuvastatin pharmacokinetics in dogs 
might further aid in elucidating a food-effect mechanism (Lentz, 2008).  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